Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMDA Gamida Cell	$0.02	$0.23	$0.03 ▼ $2.51	$2.39M	0.93	9.20 million shs	3.57 million shs
GNTA Genenta Science	$2.97 +16.5%	$3.84	$2.20 ▼ $6.81	$54.11M	0.72	5,328 shs	10,902 shs
TIL Instil Bio	$10.40 -2.9%	$11.41	$6.07 ▼ $14.00	$67.60M	1.24	26,359 shs	20,922 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMDA Gamida Cell	-8.62%	-11.18%	-95.53%	-96.30%	-99.04%
GNTA Genenta Science	-29.75%	-21.30%	-35.15%	-36.41%	-58.87%
TIL Instil Bio	0.00%	+0.09%	-5.02%	-9.40%	-16.52%

Mysterious Gold Leverage Just Announced (Ad)

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMDA Gamida Cell	0.6105 of 5 stars	3.4	2.0	0.0	0.8	0.0
GNTA Genenta Science	0.046 of 5 stars	0.0	3.0	0.0	1.7	0.0
TIL Instil Bio	2.3613 of 5 stars	3.3	3.0	1.2	3.3	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMDA Gamida Cell	2.75	Moderate Buy	$4.75	30,545.16% Upside
GNTA Genenta Science	3.00	Buy	N/A	N/A
TIL Instil Bio	2.67	Moderate Buy	$36.00	252.25% Upside

Current Analyst Ratings

Latest TIL, GNTA, and GMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/12/2024	TIL Instil Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/25/2024	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
1/29/2024	GMDA Gamida Cell	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMDA Gamida Cell	$1.78M	1.34	N/A	N/A	($0.02) per share	-0.78
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.21 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$34.72 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMDA Gamida Cell	-$63M	-$0.63	N/A	∞	N/A	N/A	N/A	-57.59%	5/20/2024 (Estimated)
GNTA Genenta Science	-$12.60M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	-$156.09M	-$23.99	N/A	N/A	N/A	N/A	-58.49%	-41.58%	5/9/2024 (Estimated)

Latest TIL, GNTA, and GMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	TIL Instil Bio	N/A	-$1.99	-$1.99	-$1.99	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMDA Gamida Cell	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMDA Gamida Cell	213.14	2.16	2.09
GNTA Genenta Science	N/A	12.25	12.25
TIL Instil Bio	0.36	15.23	15.22

Ownership

Institutional Ownership

Company	Institutional Ownership
GMDA Gamida Cell	50.34%
GNTA Genenta Science	15.13%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
GMDA Gamida Cell	3.40%
GNTA Genenta Science	28.99%
TIL Instil Bio	54.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GMDA Gamida Cell	143	154.05 million	143.70 million	Optionable
GNTA Genenta Science	14	18.22 million	12.94 million	Not Optionable
TIL Instil Bio	49	6.50 million	2.95 million	Optionable

TIL, GNTA, and GMDA Headlines

Source	Headline
	This actor once saw father saved murder accused, qualified for Olympics, then became Bollywood's top villain, died at... msn.com - April 21 at 9:58 AM
	Sustainability through global collaboration dailypioneer.com - April 19 at 7:54 PM
	Instil Bio (TIL) Price Target Decreased by 23.15% to 28.22 msn.com - April 17 at 12:21 PM
	Jefferies cuts Instil Bio to hold, cites drug discontinuation msn.com - April 12 at 1:45 PM
	Learning from nature, investing in people and ownership culture can future-proof the insight function research-live.com - March 29 at 7:34 AM
	What Makes Instil Bio (TIL) a New Buy Stock zacks.com - March 27 at 1:01 PM
	Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14 seekingalpha.com - March 22 at 10:31 AM
	Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - March 21 at 5:00 PM
	UK Treasury to overhaul crypto regulations to strengthen AML measures forbesindia.com - March 14 at 7:37 AM
	A Very Private School — Charles Spencer’s privileged but painful education ft.com - March 12 at 9:18 AM
	Jon Cruddas: ‘Labour has to rediscover its moral purpose’ theguardian.com - March 11 at 2:59 PM
	Junglee Poker launches Apne Type Ke Log campaign featuring Anil Kapoor financialexpress.com - February 24 at 7:23 PM
	Instil Bio Stock (NASDAQ:TIL) Dividends: History, Yield and Dates benzinga.com - February 24 at 12:50 AM
	TIL therapies: the impact on cancer research labiotech.eu - February 22 at 2:43 PM
	Behind the new kind of cell therapy that just won FDA approval biopharmadive.com - February 22 at 8:26 AM
	Alexei Navalny death latest: Putin brings new criminal case against critic’s brother as mother pleads for body sg.yahoo.com - February 21 at 3:33 PM
	Alexei Navalny death latest: X restores wife Yulia’s account as Putin brings new case against critic’s brother independent.co.uk - February 20 at 11:59 PM
	How RSS textbooks are reshaping Indian history and science under Modi msn.com - February 19 at 9:49 AM
	Instil Bio Inc. thestreet.com - February 16 at 4:33 AM
	Boeing in ‘last chance saloon’, Emirates boss says msn.com - February 5 at 1:41 AM
	Auto industry stakeholders react to Interim Budget 2024 financialexpress.com - February 5 at 1:41 AM
	Interim Budget 2024: On path to a brighter and more prosperous India economictimes.indiatimes.com - February 2 at 7:52 AM
	Prezident Markon’s New Singles Round-up (Okvsho, Ivan Llanes, EDKUB, Sonoras Mil, Nina Camillo, Arthur Melo and more) soundsandcolours.com - January 31 at 1:44 AM
	Amber Ray, Rapudo's Baby Africanah Lands Lucrative Products Ambassadorial Job at 8 Months tuko.co.ke - January 31 at 1:44 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Buffett Wishes He Could Buy
April 22, 2024 8:35 AM
View 3 Value Stocks Buffett Wishes He Could Buy
Best Bear Market Funds: Top 3 Investment Options to Consider
March 27, 2024 10:58 AM
View Best Bear Market Funds: Top 3 Investment Options to Consider
Power Surge: Utilities Sector's Resilience Shines
April 25, 2024 9:51 AM
View Power Surge: Utilities Sector's Resilience Shines
3 Most Active Penny Stocks: Buy, Sell, or Hold
April 4, 2024 9:25 AM
View 3 Most Active Penny Stocks: Buy, Sell, or Hold
Is DraftKings A Good Bet Ahead of Q1 Earnings?
March 27, 2024 10:45 AM
View Is DraftKings A Good Bet Ahead of Q1 Earnings?

All Headlines

Company Descriptions

Gamida Cell

NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

Genenta Science

NASDAQ:GNTA

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Instil Bio

NASDAQ:TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial